GMO-Z.com Payment Gateway India Credit Fund
GMO-Z.com Payment Gateway India Credit Fund is an impact-oriented Category II AIF managed by GMO-Z.com Payment Gateway India Private Limited, a subsidiary of GMO Payment Gateway. Its public record shows NCD financing to financial-inclusion and fintech businesses. SEBI and issuer filings identify Satya MicroCapital, Ugro Capital and Si Creva as fund-linked exposures; broader GMO lending activity is excluded from this vehicle record.
At a glance
- Founded
- 2020
- Footprint
- Gurugram / Mumbai
- Stage
- Impact private credit; NCDs to Indian financial-inclusion and fintech businesses
Research profile
Read the manager in sequence.
Open a section to inspect the evidence. The first view starts with the investment point of view; the rest stays quiet until you need it.
Investment lens
GMO-Z.com Payment Gateway India Credit Fund uses a impact private credit; ncds to indian financial-inclusion and fintech businesses approach across Microfinance, fintech, non-bank finance.
Current evidence
Si Creva’s May 2026 NSE filing names GMO-Z.com Payment Gateway India Credit Fund as an NCD holder in a March 2025 allotment. Ugro Capital’s 2026 prospectus continues to identify the fund among holders of its non-convertible securities, while GMO Payment Gateway’s 2026 interim report identifies the India credit fund as a consolidated subsidiary of the group.
Strategy
Impact private credit; NCDs to Indian financial-inclusion and fintech businesses
Sector focus
Microfinance, fintech, non-bank finance
Current signal
Si Creva’s May 2026 NSE filing names GMO-Z.com Payment Gateway India Credit Fund as an NCD holder in a March 2025 allotment. Ugro Capital’s 2026 prospectus continues to identify the fund among holders of its non-convertible securities, while GMO Payment Gateway’s 2026 interim report identifies the India credit fund as a consolidated subsidiary of the group.
Next step
Need this manager reviewed against your mandate?
Share the allocation question, ticket size, liquidity constraints and existing exposure. Rupeia can determine whether this profile needs a deeper decision-support brief.